Hotgen(SH:688068) Shang Hai Zheng Quan Bao·2025-12-02 19:12Group 1 - The core point of the announcement is that Beijing Hotgen Biotech Co., Ltd.'s important associate company, Hangzhou Aorui Biotechnology Co., Ltd., has recently obtained a Class III medical device registration certificate for independent analysis software, enhancing the company's capabilities in tumor detection products [1][3] - The software is designed to assist in the clinical diagnosis of suspected primary liver cancer by analyzing the results of specific gene methylation tests, thus improving the company's product offerings in liver cancer detection [1] - The acquisition of this qualification is expected to enhance the company's market expansion capabilities and core competitiveness in the field of cancer detection [1] Group 2 - The company has approved a share repurchase plan, allowing it to buy back a portion of its issued A-shares using its own funds, with a total repurchase amount between RMB 100 million and RMB 200 million, and a maximum repurchase price of RMB 244 per share [6][7] - As of November 30, 2025, the company has repurchased a total of 904,054 shares, accounting for 0.98% of the total share capital, with a total expenditure of approximately RMB 149.96 million [7] - The company will continue to comply with relevant regulations during the repurchase period and will disclose progress updates in a timely manner [9]